Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

[Treatment of patients with relapsed or refractory diffuse large B-cell lymphoma].

Niitsu N.

Nihon Rinsho. 2012 Apr;70 Suppl 2:509-13. Japanese. No abstract available.

PMID:
23134007
2.

Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.

Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM.

Br J Haematol. 2008 Oct;143(2):268-73. doi: 10.1111/j.1365-2141.2008.07342.x. Epub 2008 Aug 10.

PMID:
18699848
3.
4.

Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.

Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K, Linch DC, Ardeshna K.

Br J Haematol. 2012 Jun;157(5):543-52. doi: 10.1111/j.1365-2141.2012.09096.x. Epub 2012 Mar 20.

PMID:
22429186
5.

Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.

Nademanee A, Forman SJ.

Semin Hematol. 2006 Oct;43(4):240-50. Review.

PMID:
17027658
6.

[Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].

Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M.

Gan To Kagaku Ryoho. 2005 Dec;32(13):2059-64. Japanese.

PMID:
16352929
7.

Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.

Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E.

Bone Marrow Transplant. 2002 Mar;29(6):473-7.

8.

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.

Martín A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea.

Haematologica. 2009 May;94(5):744. doi: 10.3324/haematol.2009.006452. Epub 2009 Mar 31. No abstract available.

9.

[Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].

Satoh T, Tsushima K, Hizawa Y, Nakui Y, Itoh J, Tamura Y, Saitoh S, Taka-mi H, Munakata A, Kawamura S.

Gan To Kagaku Ryoho. 1997 Apr;24(6):733-6. Japanese. No abstract available.

PMID:
9126313
10.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
11.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
13.

High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H.

Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Review.

PMID:
21241276
14.

Pharmacotherapy of large B-cell lymphoma.

Escalón MP, Lossos IS.

Expert Opin Pharmacother. 2008 Sep;9(13):2247-58. doi: 10.1517/14656566.9.13.2247 . Review.

PMID:
18710350
15.

[Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma].

Wang XX, Huang HQ, Xia ZJ, Lin XB, Cai QQ, Gao Y, Lin ZX, Lin TY, Jiang WQ.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Apr;30(4):867-70. Chinese.

PMID:
20423868
16.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.

J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.

PMID:
21947824
17.

Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.

Moore S, Peggs K, Thomson K, Lowry L, Ljubic A, Goldstone AH, Linch DC, Ardeshna KM.

Br J Haematol. 2012 Jan;156(1):142-3. doi: 10.1111/j.1365-2141.2011.08818.x. Epub 2011 Aug 16. No abstract available.

PMID:
21848889
18.

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.

Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH.

Blood. 2004 May 15;103(10):3684-8. Epub 2004 Jan 22.

19.

Who should receive myeloablative therapy for diffuse large B-cell lymphoma?

Wannesson L, Zucca E.

Nat Clin Pract Oncol. 2008 Aug;5(8):442-3. doi: 10.1038/ncponc1175. Epub 2008 Jul 8. No abstract available.

PMID:
18607392
20.

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).

Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22.

Supplemental Content

Support Center